Scarica l'app Stockscreener
351.80
3.74%
12.69
Dopo l'orario di chiusura:
351.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Receives Analyst Rating Update fr - GuruFocus
Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity? - simplywall.st
Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
ALNY: Morgan Stanley Adjusts Price Target Amidst Equal-Weight Ra - GuruFocus
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential - Investing.com Canada
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $510.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Buy Rating on ALNY, Lowers Price T - GuruFocus
What analysts say about Alnylam Pharmaceuticals Inc. stockGold Moves & Safe Swing Trade Setups - mfd.ru
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy - Finviz
What Alnylam Pharmaceuticals (ALNY)'s Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders - simplywall.st
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Whale Trades: Should I hold or sell Alnylam Pharmaceuticals Inc nowWeekly Profit Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Barclays Initiates Coverage on Alnylam Pharmaceuticals (ALNY) wi - GuruFocus
Street Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividendQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
J. Safra Sarasin Holding AG Has $4.34 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile - Chartmill
Federated Hermes Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook - Intellectia AI
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression - Finviz
Aug Shorts: Is Alnylam Pharmaceuticals Inc impacted by rising rates2025 Earnings Impact & Safe Investment Capital Preservation Plans - baoquankhu1.vn
EFG Asset Management North America Corp. Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What are analysts’ price targets for Alnylam Pharmaceuticals Inc.Weekly Gains Summary & Stepwise Entry and Exit Trade Signals - mfd.ru
The Five Minute Read - Lowell Sun
Mitsubishi UFJ Trust & Banking Corp Sells 8,273 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2026 Revenue Guidance Signals Strong Growth Potential - simplywall.st
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Jennison Associates LLC Has $139.02 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest - MarketBeat
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
1.92%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):